purine rich element binding protein AGenealiases: MRD31 · NEDRIHF · PUR-ALPHA · PUR1 · PURALPHA
Q-omics provides the consensus-scored PURA profile across patient tissues and cancer cell-line models. PURA expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PURA is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, PURA protein abundance shows 34,537 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where PURA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PURA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PURA survival associations across molecular data types. PURA RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PURA RNA expression–survival associations across cancer types. High PURA expression shows unfavorable associations in HNSC, MESO, CESC and ESCA, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PURA RNA expression.
This table summarizes PURA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PURA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PURA shows lower tumor expression in THCA, UCEC, LUSC, LUAD, BLCA and BRCA. The THCA box plot shows higher PURA RNA expression in normal versus tumor tissue (log2 FC = −0.728, t-test p < 0.001).
This table shows molecular features associated with PURA in patient tissues and cancer cell lines. In patient samples, PURA shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PURA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
